News
Momcozy Debuts New Maternal Care Innovations at ABC Kids Expo 2026
2+ hour, 14+ min ago (285+ words) LAS VEGAS, May 14, 2026 /PRNewswire/ --Momcozy, the global leader in wearable breast pumps and maternal care innovation, today announced the debut of several new maternal care offerings at ABC Kids Expo 2026, reinforcing the brand's continued commitment to developing technology designed around…...
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
1+ mon, 1+ week ago (241+ words) In addition to the neoadjuvant Phase III study (KN026-004) that has met its primary endpoint, the adjuvant Phase III study (KN026-007) completed first patient dosing in March 2026 and plans to enroll approximately 1, 800 patients with high recurrence risk after surgery. Domestically developed bispecific…...
Emagine Solutions Technology Wins ACA Grant, Announces Open Application for Groundbreaking Arizona Maternal Health Study
1+ mon, 3+ week ago (198+ words) TUCSON, Ariz. , March 24, 2026--(BUSINESS WIRE)--Emagine Solutions Technology today announced that the Arizona Commerce Authority (ACA) has awarded the maternal health innovator a coveted $250, 000 grant through its Wear Tech Applied Research Center. Emagine is now seeking participants for its maternal…...
Kisqali" Receives Positive Draft Recommendation From Canada's Drug Agency For All Eligible Early Breast Cancer Patients at High Risk of Recurrence
3+ mon, 1+ week ago (926+ words) The draft recommendation for Kisqali" (ribociclib tablets) from Canada's Drug Agency (CDA-AMC) supports public reimbursement for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II-III early breast cancer (e BC) in patients at high risk of recurrence....